US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
China Adds MP Materials, USA Rare Earth to Export Control List Amid Escalating U.S.-China Trade Tensions 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
Ukrainian Drone Makers Target Japan and Asia Defense Market 
100+ Global Companies Push Governments to Prioritize Electrification for Economic Growth 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Trump Says Anthropic No Longer Seen as National Security Threat 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Qualcomm Nears $4 Billion Acquisition of AI Chip Startup Modular 
SCHAUMBURG, Ill., Feb. 03, 2016 -- Sagent Pharmaceuticals, Inc. (NASDAQ:SGNT) a leader of specialty pharmaceutical products with a specific emphasis on the injectable market, today announced that it will release financial results for the 2015 fourth quarter and full year pre-market on Tuesday, February 16, 2016 and will host a teleconference and webcast at 9 a.m. ET to review the results.
Interested parties may access the live call by dialing:
Within the United States: 877-293-5456
International: 707-287-9357
A live webcast of the teleconference will be available on the company's website at: http://investor.sagentpharma.com/events.cfm.
A replay of the presentation will be available on the Sagent website or by dialing:
Toll-Free: 855-859-2056
Passcode: 45341464
The replay will be available until February 29, 2016.
About Sagent Pharmaceuticals, Inc.
Sagent Pharmaceuticals, Inc., founded in 2006, is a global specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectables. Sagent has created a unique, global network of resources, comprising rapid development capabilities, sophisticated manufacturing and innovative drug delivery technologies, resulting in an extensive and rapidly expanding pharmaceutical product portfolio that fulfills the evolving needs of patients.
INVESTOR CONTACT: Jonathon Singer, Sagent 847-908-1605 [email protected]
